125 related articles for article (PubMed ID: 9607573)
1. Phase I clinical trial of perillyl alcohol administered daily.
Ripple GH; Gould MN; Stewart JA; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Pomplun M; Wilding G; Bailey HH
Clin Cancer Res; 1998 May; 4(5):1159-64. PubMed ID: 9607573
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Ripple GH; Gould MN; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Binger K; Tutsch KD; Pomplun M; Wahamaki A; Marnocha R; Wilding G; Bailey HH
Clin Cancer Res; 2000 Feb; 6(2):390-6. PubMed ID: 10690515
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of perillyl alcohol in patients with refractory malignancies.
Murren JR; Pizzorno G; DiStasio SA; McKeon A; Peccerillo K; Gollerkari A; McMurray W; Burtness BA; Rutherford T; Li X; Ho PT; Sartorelli A
Cancer Biol Ther; 2002; 1(2):130-5. PubMed ID: 12170772
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of perillyl alcohol administered four times daily continuously.
Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
[TBL] [Abstract][Full Text] [Related]
7. Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma.
Zhang Z; Chen H; Chan KK; Budd T; Ganapathi R
J Chromatogr B Biomed Sci Appl; 1999 May; 728(1):85-95. PubMed ID: 10379660
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
Bailey HH; Attia S; Love RR; Fass T; Chappell R; Tutsch K; Harris L; Jumonville A; Hansen R; Shapiro GR; Stewart JA
Cancer Chemother Pharmacol; 2008 Jun; 62(1):149-57. PubMed ID: 17885756
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Azzoli CG; Miller VA; Ng KK; Krug LM; Spriggs DR; Tong WP; Riedel ER; Kris MG
Cancer Chemother Pharmacol; 2003 Jun; 51(6):493-8. PubMed ID: 12695855
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
Vigushin DM; Poon GK; Boddy A; English J; Halbert GW; Pagonis C; Jarman M; Coombes RC
Cancer Chemother Pharmacol; 1998; 42(2):111-7. PubMed ID: 9654110
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
13. R-Limonene metabolism in humans and metabolite kinetics after oral administration.
Schmidt L; Göen T
Arch Toxicol; 2017 Mar; 91(3):1175-1185. PubMed ID: 27325307
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity and biotransformation of the anticancer drug perillyl alcohol in PC12 cells and in the rat.
Boon PJ; van der Boon D; Mulder GJ
Toxicol Appl Pharmacol; 2000 Aug; 167(1):55-62. PubMed ID: 10936079
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.
Bailey HH; Levy D; Harris LS; Schink JC; Foss F; Beatty P; Wadler S
Gynecol Oncol; 2002 Jun; 85(3):464-8. PubMed ID: 12051875
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats.
de Lima DC; Rodrigues SV; Boaventura GT; Cho HY; Chen TC; Schönthal AH; Da Fonseca CO
Drug Test Anal; 2020 Feb; 12(2):268-279. PubMed ID: 31800149
[TBL] [Abstract][Full Text] [Related]
17. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.
Berlin J; Tutsch KD; Hutson P; Cleary J; Rago RP; Arzoomanian RZ; Alberti D; Feierabend C; Wilding G
J Clin Oncol; 1997 Feb; 15(2):781-9. PubMed ID: 9053505
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Rowinsky EK; Noe DA; Ettinger DS; Christian MC; Lubejko BG; Fishman EK; Sartorius SE; Boyd MR; Donehower RC
Cancer Res; 1993 Apr; 53(8):1794-801. PubMed ID: 8467498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
